Informações:
Falhas:
ID
35129
Descrição
GIOTRIF in First Line Therapy of Advanced NSCLC With EGFR-mutations; ODM derived from: https://clinicaltrials.gov/show/NCT02047903
Link
https://clinicaltrials.gov/show/NCT02047903
Palavras-chave
Versões (1)
- 19/02/2019 19/02/2019 -
Titular dos direitos
See clinicaltrials.gov
Transferido a
19 de fevereiro de 2019
DOI
Para um pedido faça login.
Licença
Creative Commons BY 4.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
Eligibility Carcinoma, Non-Small-Cell Lung NCT02047903
Eligibility Carcinoma, Non-Small-Cell Lung NCT02047903
- StudyEvent: Eligibility
Similar models
Eligibility Carcinoma, Non-Small-Cell Lung NCT02047903
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
EGFR tyrosine kinase inhibitor Absent | Non-Small Cell Lung Carcinoma Advanced Locally | Non-small cell lung cancer metastatic | EGFR Activating Mutation
Item
egfr- tyrosine kinase inhibitor (tki) naive patients with histologically confirmed locally advanced or metastatic nsclc with activating egfr-mutations
boolean
C1443775 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
C0007131 (UMLS CUI [2,1])
C0205179 (UMLS CUI [2,2])
C1517927 (UMLS CUI [2,3])
C0278987 (UMLS CUI [3])
C2984891 (UMLS CUI [4])
C0332197 (UMLS CUI [1,2])
C0007131 (UMLS CUI [2,1])
C0205179 (UMLS CUI [2,2])
C1517927 (UMLS CUI [2,3])
C0278987 (UMLS CUI [3])
C2984891 (UMLS CUI [4])
Age
Item
age >= 18 years
boolean
C0001779 (UMLS CUI [1])
Therapeutic procedure Initiation | Afatinib
Item
patients for whom the treating physician has decided to initiate treatment with giotrif
boolean
C0087111 (UMLS CUI [1,1])
C1704686 (UMLS CUI [1,2])
C2987648 (UMLS CUI [2])
C1704686 (UMLS CUI [1,2])
C2987648 (UMLS CUI [2])
Informed Consent
Item
written informed consent prior inclusion
boolean
C0021430 (UMLS CUI [1])
Medical contraindication Afatinib
Item
contraindication for afatinib according to the summary of product characteristics
boolean
C1301624 (UMLS CUI [1,1])
C2987648 (UMLS CUI [1,2])
C2987648 (UMLS CUI [1,2])
Study Subject Participation Status
Item
participation in another clinical study until 30 days after end of treatment
boolean
C2348568 (UMLS CUI [1])
Systemic Chemotherapy
Item
prior systemic chemotherapy (neo-/adjuvant therapy is permitted if at least 12 months has elapsed prior to disease progression)
boolean
C1883256 (UMLS CUI [1])
EGFR tyrosine kinase inhibitor Previous
Item
previous treatment with an egfr-tyrosine kinase inhibitor
boolean
C1443775 (UMLS CUI [1,1])
C0205156 (UMLS CUI [1,2])
C0205156 (UMLS CUI [1,2])
Quality of life Questionnaires Completion Unwilling | Quality of life Questionnaires Completion Unable
Item
patients not willing or not able to fill in quality of life questionnaires
boolean
C0034380 (UMLS CUI [1,1])
C0034394 (UMLS CUI [1,2])
C0205197 (UMLS CUI [1,3])
C0558080 (UMLS CUI [1,4])
C0034380 (UMLS CUI [2,1])
C0034394 (UMLS CUI [2,2])
C0205197 (UMLS CUI [2,3])
C1299582 (UMLS CUI [2,4])
C0034394 (UMLS CUI [1,2])
C0205197 (UMLS CUI [1,3])
C0558080 (UMLS CUI [1,4])
C0034380 (UMLS CUI [2,1])
C0034394 (UMLS CUI [2,2])
C0205197 (UMLS CUI [2,3])
C1299582 (UMLS CUI [2,4])
Legal capacity Missing | Legal capacity Impaired
Item
patients with missing or impaired legal capacity
boolean
C0683673 (UMLS CUI [1,1])
C1705492 (UMLS CUI [1,2])
C0683673 (UMLS CUI [2,1])
C0221099 (UMLS CUI [2,2])
C1705492 (UMLS CUI [1,2])
C0683673 (UMLS CUI [2,1])
C0221099 (UMLS CUI [2,2])
Pregnancy
Item
pregnancy
boolean
C0032961 (UMLS CUI [1])